Event Details:
April 10th - 13th | Hilton Bayfront San Diego, CA
Applied BioMath Presence:
Day and Time: Tuesday, April 11th | 9:40am PT
Title: QSP Modeling to inform R&D decisions: Differentiation of ASP2453 and Targeted Protein Degrader Strategies
Abstract: ASP2453 is a KRASG12C inhibitor. Preclinical data suggests impressive efficacy yet it was unclear if it would show a more favorable clinical response compared to competitors. A QSP model linked to tumor growth in patients with NSCLC predicted ASP2453 exhibits greater clinical response than AMG 510, supporting potential differentiation and critical thinking for clinical trials. In some instances, pre-built TPD models can be used to more expeditiously assess TPD strategies targeting KRAS.
Presenter: Kas Subramanian, PhD, Executive Director of Modeling at Applied BioMath
The research performed in one vignette of this presentation was conducted by the following authors:
Hiroyuki Sayama 1, Diana Marcantonio 2, Takeyuki Nagashima 1, Masashi Shimazaki 3, Tsuyoshi Minematsu 1, Joshua F Apgar 2, John M Burke 2, Lucia Wille 2, Yasuhisa Nagasaka 1, Daniel C Kirouac 2
1 Astellas Pharma Inc, Ibaraki, Japan.
2 Applied BioMath LLC, Concord, Massachusetts, USA.
3 Astellas Research Institute of America LLC, Northbrook, Illinois, USA.
This study was supported through funding from Astellas Pharm Inc.